The Virtual Investor “Why Now” On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, concluded on August 27, 2026, after spotlighting nine emerging healthcare and biotech companies.
The on-demand format was designed to give investors and analysts direct access to management teams, each presenting why now is the right moment for their company’s story.
AIM ImmunoTech Inc. (AIM), an immune-oncology company, shared progress on Ampligen, its investigational dsRNA and highly selective TLR3 agonist immune-modulator with broad-spectrum clinical activity.
Chairman and CEO Thomas Equels highlighted Ampligen’s Phase 2 DURIPANC trial in metastatic pancreatic cancer, noting final patient dosing and a transition into primary endpoint evaluation in Q4 2026, with topline results expected in Q1 2027.
AIM closed Friday’s trading at $0.25, up 3.36%, with Ampligen also being evaluated in combination with AstraZeneca’s anti-PD-L1 checkpoint inhibitor Imfinzi (durvalumab).
Akari Therapeutics, Plc (AKTX) outlined its antibody drug conjugate platform, with President and CEO Abizer Gaslightwala emphasizing the demand for differentiated payloads in the evolving ADC landscape.
Akari’s lead candidate AKTX-101 is a Trop2-targeting ADC advancing toward a Phase 1 first-in-human trial by mid-2027, while AKTX-102 targets CEACAM5 across multiple solid tumors, and AKTX closed Friday at $10.70, up 18.76%.
CNS Pharmaceuticals, Inc. (CNSP) presented its strategic transformation, with President and CEO Rami Levin pointing to a strengthened leadership team, improved financial position, and disciplined asset evaluation as the company advances Berubicin for glioblastoma multiforme.
Moleculin Biotech, Inc. (MBRX) highlighted encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia, with Chairman and CEO Walter underscoring Annamycin’s lack of cardiotoxicity common to anthracyclines.
Key milestones for Moleculin include enrollment progress and an upcoming 90-patient interim analysis, with MBRX closing Friday’s trading at $0.64, down 5.63%.
Ernexa Therapeutics, Inc. (ERNA) shared its transition into a clinical-stage biotech, with President and CEO Sanjeev Luther presenting lead candidate ERNA-101, an allogeneic induced mesenchymal stem cell therapy designed to deliver IL-7/IL-15 cytokines directly into the tumor microenvironment.
ERNA-101 aims to activate T cells and NK cells to overcome immunologically cold tumors, with a Phase 1 study in platinum-resistant ovarian cancer expected to launch in Q4 2026, and ERNA closed Friday at $4.57, down 2.14%.
GRI Bio Inc. (GRI) outlined its differentiated approach to idiopathic pulmonary fibrosis, with CEO Marc Hertz, Ph.D., highlighting lead candidate GRI-0621, a once-daily oral RARb/g agonist with late-breaking Phase 2a data presented at the 2026 European Respiratory Society Congress.
Daré Bioscience, Inc. (DARE) focused on women’s health, with President and CEO Sabrina Martucci Johnson highlighting the launch of Flora Sync LF5, the Phase 3 hormone-free contraceptive Ovaprene, and DARE-HPV advancing into Phase 2 with funding from an ARPA-H award targeting approximately 100 women, with topline results anticipated in 2027.
enVVeno Medical Corporation (NVNO) presented its bioprosthetic venous valve enVVe, with CEO Robert Berman highlighting recent FDA IDE approval for the pivotal TAVVE trial, expected to begin in Q4 2026 and enroll about 230 patients across up to 40 sites, with NVNO closing Friday at $10.75, down 6.28%.
Outlook Therapeutics, Inc. (OTLK) rounded out the conference with CEO Bob Jahr emphasizing the July 24, 2026 FDA approval of LYTENAVA (bevacizumab-vikg) for wet AMD, with the company guiding that annual U.S. LYTENAVA sales could exceed $500 million by 2030, and OTLK closing Friday at $0.64, up 0.59%.
